2022
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.
HÁJKOVÁ, Monika, Tomáš ANDRAŠINA, Petra OVESNÁ, Tomáš ROHAN, Marek DOSTÁL et. al.Základní údaje
Originální název
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.
Autoři
HÁJKOVÁ, Monika (203 Česká republika, garant, domácí), Tomáš ANDRAŠINA (703 Slovensko, domácí), Petra OVESNÁ (203 Česká republika, domácí), Tomáš ROHAN (203 Česká republika, domácí), Marek DOSTÁL (203 Česká republika, domácí), Vlastimil VÁLEK (203 Česká republika, domácí), Lenka OSTŘÍŽKOVÁ (203 Česká republika), Štěpán TUČEK (203 Česká republika), Jiří ŠEDO (203 Česká republika) a Igor KISS (203 Česká republika)
Vydání
In vivo, KAPANDRITI, International Institute of Anticancer Research, 2022, 0258-851X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30224 Radiology, nuclear medicine and medical imaging
Stát vydavatele
Řecko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.300
Kód RIV
RIV/00216224:14110/22:00127050
Organizační jednotka
Lékařská fakulta
UT WoS
000863324700016
Klíčová slova anglicky
Hepatocellular carcinoma; transarterial chemoembolization; RECIST; mRECIST; volumetric analysis
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2023 12:45, Mgr. Tereza Miškechová
Anotace
V originále
Background/Aim: To evaluate the prognostic value of Response Evaluation Criteria In Solid Tumors (RECIST), modified RECIST and volumetric analysis in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). Patients and Methods: This single-center prospective cohort study included a total of 61 patients with HCC treated by transarterial chemoembolization (TACE). The response of TACE was evaluated on preprocedural and postprocedural CT by two radiologists using RECIST/mRECIST and volumetric response to treatment. Each response assessment method was used to classify the response as progressive disease, stable disease, partial response and complete response. Kaplan-Meier analysis with log-rank test was performed for each method to evaluate its ability to help predict overall survival and progression free survival. Interobserver variability and reproducibility was determined by the Pearson and Spearman correlation coefficients. Results: The median overall survival was 17.1 months and the median progression-free survival was 11.1 months. Volumetric assessment was proved to be a prognostic factor for overall survival (p<0.01) and progression-free survival (p<0.001), contrasting with RECIST and mRECIST. All three methods featured very small interobserver variability (p<0.001 for Pearson and Spearman correlation coefficients). The patients classified as having stable disease had a 3.8-fold higher risk of death than the patients classified as having a complete/partial response (HR=3.82; 95% Confidence Interval (CI)=1.32-11.02; p=0.013) and a 4.5-fold higher risk of progression (HR=4.46; 95% CI=1.72-11.61; p=0.002). Conclusion: The prognostic value of volumetric analysis in patients with HCC treated by TACE appears to be superior to RECIST and mRECIST, with a real impact in everyday practice.
Návaznosti
MUNI/A/1388/2021, interní kód MU |
|